Keith E Stockerl-Goldstein
Overview
Explore the profile of Keith E Stockerl-Goldstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiala M, Silberstein A, Schroeder M, Stockerl-Goldstein K, Vij R
Clin Lymphoma Myeloma Leuk
. 2023 Feb;
23(4):266-272.
PMID: 36754693
Introduction/background: People with multiple myeloma are at risk for financial toxicity due to the high cost of treatment and prolonged treatment duration. However, little data exist regarding financial toxicity among...
2.
Rubinstein S, Bhutani D, Lynch R, Hsu C, Shyr Y, Advani S, et al.
Blood Cancer Discov
. 2022 Mar;
3(3):181-193.
PMID: 35262738
Significance: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the...
3.
Berrien-Elliott M, Becker-Hapak M, Cashen A, Jacobs M, Wong P, Foster M, et al.
Blood
. 2021 Nov;
139(8):1177-1183.
PMID: 34797911
Natural killer (NK) cells are a promising alternative to T cells for cancer immunotherapy. Adoptive therapies with allogeneic, cytokine-activated NK cells are being investigated in clinical trials. However, the optimal...
4.
Xiang J, Shi M, Fiala M, Gao F, Rettig M, Uy G, et al.
Blood Adv
. 2021 Sep;
6(7):1991-2000.
PMID: 34555850
Mobilized peripheral blood has become the primary source of hematopoietic stem cells for both autologous and allogeneic stem cell transplantation. Granulocyte colony-stimulating factor (G-CSF) is currently the standard agent used...
5.
Barnell E, Newcomer K, Skidmore Z, Krysiak K, Anderson S, Wartman L, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036230
Purpose: Physicians treating hematologic malignancies increasingly order targeted sequencing panels to interrogate recurrently mutated genes. The precise impact of these panels on clinical decision making is not well understood. Methods:...
6.
Fiala M, King J, Feinberg D, Goldsmith S, Schroeder M, Ghobadi A, et al.
Bone Marrow Transplant
. 2021 Apr;
56(8):2016-2018.
PMID: 33875814
No abstract available.
7.
Zhang K, Zhang R, Deych E, Stockerl-Goldstein K, Gorcsan 3rd J, Lenihan D
Am Heart J
. 2020 Nov;
232:137-145.
PMID: 33212046
Background: Timely recognition of cardiac amyloidosis is clinically important, but the diagnosis is frequently delayed. Objectives: We sought to identify a multi-modality approach with the highest diagnostic accuracy in patients...
8.
Berrien-Elliott M, Cashen A, Cubitt C, Neal C, Wong P, Wagner J, et al.
Cancer Discov
. 2020 Aug;
10(12):1854-1871.
PMID: 32826231
Natural killer (NK) cells are an emerging cancer cellular therapy and potent mediators of antitumor immunity. Cytokine-induced memory-like (ML) NK cellular therapy is safe and induces remissions in patients with...
9.
Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D, et al.
Lancet
. 2020 Jun;
395(10241):1907-1918.
PMID: 32473681
Background: Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors...
10.
Fiala M, Vosuri V, Goldsmith S, Schroeder M, Ghobadi A, Wildes T, et al.
Bone Marrow Transplant
. 2019 Aug;
55(6):1188-1190.
PMID: 31462683
No abstract available.